SMART syndrome can mimic brain tumor recurrence years after cranial radiotherapy

Two patients developed reversible unilateral cortical enhancement and neurological deficits four and nine years after cranial RT, mimicking tumor recurrence.

KEY POINTS

  • This teaching case report describes two patients who developed stroke-like migraine attacks after radiation therapy (SMART) syndrome several years after cranial irradiation. Both had previously received 60 Gy in 30 fractions: a 55-year-old man with recurrent WHO grade 3 solitary fibrous tumor/hemangiopericytoma, presenting four years after RT, and a 53-year-old man with neurofibromatosis type 2 and recurrent WHO grade 2 meningioma, presenting nine years after RT.
  • SMART syndrome is a rare delayed complication characterized by transient neurological deficits, seizures, headache and reversible cortical imaging abnormalities, although the complete clinical triad is not always present. In both cases, focal neurological deficits preceded seizure activity, including visual disturbances in the first patient and aphasia with ataxia in the second, demonstrating that seizures need not be the initial presentation.
  • The characteristic MRI finding was unilateral gyriform cortical enhancement with associated swelling and T2/FLAIR abnormalities, confined to previously irradiated brain tissue rather than following a vascular territory. These changes were initially concerning for tumor progression or leptomeningeal disease, but their non-mass-like appearance and subsequent reversibility supported SMART syndrome.
  • Case 1 presented with headaches, left-sided photopsias, homonymous hemianopia and suspected occipital seizures. MRI demonstrated right occipital gyriform enhancement, associated leptomeningeal enhancement and a separate 1.4-cm enhancing focus near the prior surgical site. Increased perfusion favored SMART syndrome over radiation necrosis, which more commonly shows hypoperfusion. Following dexamethasone and levetiracetam, symptoms improved substantially and cortical enhancement decreased by three weeks, with continued improvement at four months.
  • Case 2 presented with approximately two weeks of progressive aphasia, word-finding difficulty and ataxia, followed by electroencephalographically confirmed focal seizures. MRI showed left frontal cortical swelling and gyriform enhancement within the previously irradiated region. Antiepileptic treatment was intensified with lacosamide and clobazam in addition to levetiracetam, alongside corticosteroids; the patient returned to neurological baseline within 11 days, with near-complete radiographic resolution.
  • The differential diagnosis includes tumor recurrence, leptomeningeal disease, radiation necrosis, postictal cortical changes, ischemic stroke and posterior reversible encephalopathy syndrome (PRES). The accompanying imaging comparison highlights distinguishing features: tumor recurrence is generally mass-like and progressive; radiation necrosis often shows persistent enhancement and hypoperfusion; ischemic stroke follows vascular territories; and PRES more commonly involves bilateral subcortical white matter. SMART remains a diagnosis of exclusion, and short-interval MRI is particularly informative.
  • Reversibility is characteristic but complete neurological recovery is not guaranteed. The authors cite previous series reporting incomplete recovery in approximately one-third to nearly half of affected patients and recurrence in 45% in one multicenter cohort. These historical findings are not outcomes from the two presented cases, and there is no standardized, prospectively validated treatment regimen; corticosteroids and seizure management remain individualized.

CLINICAL TAKEAWAY

In patients with previous cranial radiotherapy, new focal neurological deficits and unilateral gyriform cortical enhancement should prompt consideration of SMART syndrome before assuming tumor recurrence or radiation necrosis. Recognition of the characteristic MRI distribution, comparison with previous radiation fields, appropriate exclusion of alternative diagnoses and short-interval follow-up may prevent unnecessary oncological treatment escalation, although these two cases cannot establish the effectiveness of any specific intervention.

SOURCE

Advances in Radiation Oncology

Browse more research Suggest a correction